Covid-19 roundup: EMA starts rolling re­view of As­traZeneca vac­cine; No­vavax ex­ecs sell mil­lions in stock ahead of PhI­II

Though stud­ies for the Covid-19 vac­cine be­ing de­vel­oped by As­traZeneca and Ox­ford Uni­ver­si­ty re­searchers re­main on hold in the US, Eu­rope is speed­ing up its re­view.

The EMA an­nounced Thurs­day that it is ini­ti­at­ing the first rolling re­view of the vac­cine can­di­date, a move that would ac­cel­er­ate the fu­ture ap­proval process. By do­ing so, the agency’s hu­man med­i­cines com­mit­tee has start­ed eval­u­at­ing the first batch of da­ta, though it not­ed that much of the ev­i­dence has yet to be sub­mit­ted.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.